In recent years, some biomarkers in the blood circulation have shown value in predicting the response of patients to immunotherapy, such as PD-1+CD8+ T cells [14], CD4+ T cells [15], TCR repertoire [16, 17], cell-free DNA, circulating tumor cells, and cytokines [18]. This evidence concerns the gene CD8A and neoplasm.